Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $29.20.

Several equities research analysts recently issued reports on KURA shares. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $26.00 to $19.00 in a research note on Monday. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in Kura Oncology during the second quarter worth about $196,000. Alethea Capital Management LLC raised its position in shares of Kura Oncology by 2.4% during the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after buying an additional 6,300 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the period. AQR Capital Management LLC increased its stake in Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after acquiring an additional 58,422 shares during the last quarter. Finally, Armistice Capital LLC raised its position in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares during the period.

Kura Oncology Trading Up 0.8 %

Shares of KURA stock opened at $18.21 on Wednesday. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -8.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The stock has a 50 day simple moving average of $19.58 and a 200-day simple moving average of $20.27.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter last year, the firm earned ($0.53) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts expect that Kura Oncology will post -2.45 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.